JP5977347B2 - Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 - Google Patents
Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 Download PDFInfo
- Publication number
- JP5977347B2 JP5977347B2 JP2014519057A JP2014519057A JP5977347B2 JP 5977347 B2 JP5977347 B2 JP 5977347B2 JP 2014519057 A JP2014519057 A JP 2014519057A JP 2014519057 A JP2014519057 A JP 2014519057A JP 5977347 B2 JP5977347 B2 JP 5977347B2
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- fluoro
- phenyl
- chloro
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/14—[b, e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
Description
本出願は、2011年7月1日に出願された米国仮出願No.61/503830の利益を請求し、これは全範囲において参照として本明細書に組み込まれる。
本発明は、プレゲノムRNAカプシド形成阻害剤として有益な、B型肝炎ウィルス(HBV)感染および関連疾患の処置のために有用な化合物および方法を記載する。
B型肝炎ウィルス(HBV)感染は、依然として主要な公衆衛生問題のままである。現在、世界中で推計3億5千万人の人々および米国内で140万人が、慢性的にHBVに感染している(McMahon, 2005)。処置せずに放置した場合、これらの個人の約3分の1が、肝硬変および肝細胞癌などの重篤な肝疾患により死亡するであろう(Lee, 1997; Lok, 2004)。
臨床的に、プレゲノムRNA(pg)カプシド形成の阻害は以下の治療的利点を提供する:第1に、プレゲノムRNA(pg)カプシド形成の阻害は、現在の医薬に耐性がない、または現在の医薬から利益を享受しない患者の部分母集団のための追加の選択肢を提供することにより、現在の医薬を補完するであろう(Akbar et al., 2009; Liaw, 2009; Peters, 2009; Wiegand, van Bommel, およびBerg)。第2に、これらの特徴のある抗ウィルス機構に基づいて、プレゲノムRNA(pg)カプシド形成の阻害は、現在入手可能なDNAポリメラーゼ阻害剤に耐性のあるHBV変異体に対し有効であろう(ZoulimおよびLocarnini, 2009)。第3に、ヒト免疫不全ウイルス(HIV)感染のための高活性抗レトロウイルス療法(HAART)のように(EsteおよびCihlar)、プレゲノムRNA(pg)カプシド形成の阻害剤のDNAポリメラーゼ阻害剤との併用治療は、HVB複製を相乗的に抑制し、薬剤耐性の発生を回避し、およびしたがって慢性B型肝炎感染のためのより安全かつより効果的な処置を提供するであろう。
発明の概要
R1は、水素である;
R2は、水素、メチル、トリフルオロメチル、フッ素および塩素からなる群から選択される;
R3は、水素、メチル、フッ素および塩素からなる群から選択される;
R4は、水素、フッ素、塩素およびメチルからなる群から選択される;
R5は、水素および塩素からなる群から選択される;
R7は、水素、塩素、フッ素および臭素からなる群から選択される;
R9は、水素、メチル、フッ素および塩素からなる群から選択される;
Rxは、NH2,
Rxは、
R10は、水素、メチル、塩素および臭素からなる群から選択される;
Ryは、
プレゲノムRNAカプシド形成阻害剤
R1は、水素である;
R2は、水素、メチル、トリフルオロメチル、フッ素および塩素からなる群から選択される;
R3は、水素、メチル、フッ素および塩素からなる群から選択される;
R4は、水素、フッ素、塩素およびメチルからなる群から選択される;
R5は、水素および塩素からなる群から選択される;
R7は、水素、塩素、フッ素および臭素からなる群から選択される;
R9は、水素、メチル、フッ素および塩素からなる群から選択される;
Rxは、NH2,
Rxは、
R10は、水素、メチル、塩素および臭素からなる群から選択される;
Ryは、
例
配合物
手順
Claims (7)
- 少なくとも1種の式(I):
R1は、水素であり;
R2は、水素、メチル、トリフルオロメチル、フッ素および塩素からなる群から選択され;
R3は、水素、フッ素および塩素からなる群から選択され;
R4は、水素、フッ素、塩素およびメチルからなる群から選択され;
R5は、水素および塩素からなる群から選択され;
R7は、水素、塩素、フッ素および臭素からなる群から選択され;
R9は、水素、メチル、フッ素および塩素からなる群から選択され;
Rxは、NH2,
を有する化合物、その水和物、溶媒和物、プロドラッグ、複合体または薬学的に許容可能な塩形態を含み、任意に、少なくとも1種の薬学的に許容可能な賦形剤をさらに含む、B型肝炎ウィルス(HBV)感染および関連疾患の処置のための組成物。 - 少なくとも1種の化合物が、
2−クロロ−5−スルファモイル−N−3−メチルフェニル−ベンズアミド;
4−フルオロ−3−スルファモイル−N−(3−トリフルオロメチル−フェニル)−ベンズアミド;
N−(2−クロロ−5−トリフルオロメチル−フェニル)−4−フルオロ−3−スルファモイル−ベンズアミド;
N−フェニル−3−スルファモイル−ベンズアミド;
5−sec−ブチルスルファモイル−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
5−シクロヘプチルスルファモイル−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
N−(3,4−ジフルオロフェニル)−4−フルオロ−3−(2−メチル−シクロヘキシルスルファモイル)−ベンズアミド;
3−シクロペンチルスルファモイル−N−フェニル−ベンズアミド;
5−シクロペンチルスルファモイル−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
5−シクロペンチルスルファモイル−2−フルオロ−N−(4−フルオロ−フェニル)−ベンズアミド;
5−シクロペンチルスルファモイル−N−(3,5−ジメチルフェニル)−2−フルオロ−ベンズアミド;
3−シクロペンチルスルファモイル−4−フルオロ−N−3−メチルフェニル−ベンズアミド;
5−シクロペンチルスルファモイル−N−(3,5−ジクロロフェニル)−2−フルオロ−ベンズアミド;
3−[(フラン−2−イルメチル)−スルファモイル]−N−フェニル−ベンズアミド;
N−(3−クロロ−4−フルオロ−フェニル)−5−[(フラン−2−イルメチル)−スルファモイル]−2−フルオロ−ベンズアミド;
2−フルオロ−N−(3−フルオロ−フェニル)−5−[(フラン−2−イルメチル)−スルファモイル]−ベンズアミド;
N−(3,5−ジクロロフェニル)−2−フルオロ−5−[(フラン−2−イルメチル)−スルファモイル]−ベンズアミド;
4−フルオロ−3−[(フラン−2−イルメチル)−スルファモイル]−N−3−メチルフェニル−ベンズアミド;
5−[(4−クロロ−3−フェニルカルバモイル−ベンゼンスルホニルアミノ)−メチル]−フラン−2−カルボン酸メチルエステル;
N−フェニル−3−[(ピリジン−3−イルメチル)−スルファモイル]−ベンズアミド;
N−(3−クロロ−フェニル)−4−フルオロ−3−[(ピリジン−3−イルメチル)−スルファモイル]−ベンズアミド;
N−(3,4−ジフルオロフェニル)−2−フルオロ−5−フェネチルスルファモイル−ベンズアミド;
N−(3−クロロ−フェニル)−2−フルオロ−5−フェネチルスルファモイル−ベンズアミド;
5−ベンジルスルファモイル−N−(3−クロロ−4−フルオロ−フェニル)−2−フルオロ−ベンズアミド;
5−ベンジルスルファモイル−2−クロロ−N−フェニル−ベンズアミド;
N−(4−クロロ−フェニル)−5−[2−(3,4−ジメトキシ−フェニル)−エチルスルファモイル]−2−フルオロ-ベンズアミド;
5−(2−クロロ−ベンジルスルファモイル)−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
3−(2−クロロ−ベンジルスルファモイル)−N−(4−クロロ−フェニル)−4−フルオロ−ベンズアミド;
2−フルオロ−5−(4−メトキシ−フェニルスルファモイル)−N−3−メチルフェニル−ベンズアミド;
N−(4−クロロ−フェニル)−3−2−メチルフェニルスルファモイル−ベンズアミド;
N−フェニル−3−m−トリルスルファモイル−ベンズアミド;
N−フェニル−3−o−トリルスルファモイル−ベンズアミド;
3−(ベンジル−エチル−スルファモイル)−N−(3,4−ジフルオロフェニル)−4−フルオロ−ベンズアミド;
4−クロロ−N−フェニル−3−(チオモルホリン4−スルホニル)−ベンズアミド;
からなる群から選択される少なくとも1種である、請求項1に記載の組成物。 - 少なくとも1種の式(II):
Rxは、
を有する化合物、その水和物、溶媒和物、薬学的に許容可能な塩、プロドラッグまたは複合体を含み、任意に、少なくとも1種の薬学的に許容可能な賦形剤をさらに含む、B型肝炎ウィルス(HBV)感染および関連疾患の処置のための組成物。 - 少なくとも1種の化合物が、
5−ジエチルスルファモイル−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
5−アリルスルファモイル−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
N−(3,4−ジフルオロフェニル)−5−ジプロピルスルファモイル−2−フルオロ−ベンズアミド;
5−(アゼパン−1−スルホニル)−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
5−シクロヘキシルスルファモイル−N−(3,4−ジフルオロフェニル)−2−フルオロ−ベンズアミド;
およびこれらの薬学的に許容可能な形態からなる群から選択される少なくとも1種である、請求項3に記載の組成物。 - 少なくとも1種の式(III):
R10は、水素、メチル、塩素および臭素からなる群から選択され;
Ryは、
を有する化合物、その水和物、溶媒和物、薬学的に許容可能な塩、プロドラッグまたは複合体を含み、任意に、少なくとも1種の薬学的に許容可能な賦形剤をさらに含む、B型肝炎ウィルス(HBV)感染および関連疾患の処置のための組成物。 - 少なくとも1種の化合物が、
3−(アゼパン−1−スルホニル)−N−ベンジル−4−クロロ−ベンズアミド;
N−ベンジル−4−クロロ−3−(ピペリジン−1−スルホニル)−ベンズアミド;
N−ベンジル−4−メチル−3−(4−メチル−ピペリジン−1−スルホニル)−ベンズアミド;
N−ベンジル−3−ベンジルスルファモイル−4−メチル−ベンズアミド;
3−(3−ベンジルカルバモイル−ベンゼンスルホニルアミノ)−安息香酸;
N−ベンジル−4−ブロモ−3−ジエチルスルファモイル−ベンズアミド;
およびこれらの薬学的に許容可能な形態からなる群から選択される少なくとも1種である、請求項5に記載の組成物。 - 式(IV):
3−ジエチルスルファモイル−N−フェニル−ベンズアミド;
2−クロロ−5−ジエチルスルファモイル−N−m−トリル−ベンズアミド;
N−(4−クロロ−フェニル)−3−ジエチルスルファモイル−ベンズアミド;
5−シクロヘプチルスルファモイル−2−フルオロ−N−p−トリル−ベンズアミド;
2−ブロモ−5−シクロヘキシルスルファモイル−N−フェニル−ベンズアミド;
4−クロロ−3−シクロヘキシルスルファモイル−N−(4−フルオロ−フェニル)−ベンズアミド;
3−シクロヘキシルスルファモイル−4−メチル−N−フェニル−ベンズアミド;
N−(3−クロロ−フェニル)−5−(2−シクロヘキサ−1−エニル−エチルスルファモイル)−2−フルオロ−ベンズアミド;
5−(2−シクロヘキサ−1−エニル−エチルスルファモイル)−N−(3,5−ジメチルフェニル)−2−フルオロ−ベンズアミド;
2−フルオロ−5−(4−フルオロ−フェニルスルファモイル)−N−3−メチルフェニル−ベンズアミド;
N−(4−クロロ−フェニル)−3−(3−フルオロ−フェニルスルファモイル)−ベンズアミド;
4−メチル−N−フェニル−3−(ピペリジン−1−スルホニル)−ベンズアミド;
4−クロロ−N−(4−フルオロ−フェニル)−3−(ピペリジン−1−イルスルホニル)−ベンズアミド;
4−クロロ−N−(3−フルオロ−フェニル)−3−(モルホリン−4−スルホニル)−ベンズアミド;
これらの水和物、溶媒和物、プロドラッグ、複合体および薬学的に許容可能な塩形態、からなる群から選択される少なくとも1種を含み、任意に、少なくとも1種の薬学的に許容可能な賦形剤をさらに含む、B型肝炎ウィルス(HBV)感染および関連疾患の処置のための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161503830P | 2011-07-01 | 2011-07-01 | |
US61/503,830 | 2011-07-01 | ||
PCT/US2012/044775 WO2013006394A1 (en) | 2011-07-01 | 2012-06-29 | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016143481A Division JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014523901A JP2014523901A (ja) | 2014-09-18 |
JP2014523901A5 JP2014523901A5 (ja) | 2015-08-20 |
JP5977347B2 true JP5977347B2 (ja) | 2016-08-24 |
Family
ID=47437368
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014519057A Expired - Fee Related JP5977347B2 (ja) | 2011-07-01 | 2012-06-29 | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
JP2016143481A Expired - Fee Related JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
JP2019077562A Pending JP2019151639A (ja) | 2011-07-01 | 2019-04-16 | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016143481A Expired - Fee Related JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
JP2019077562A Pending JP2019151639A (ja) | 2011-07-01 | 2019-04-16 | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Country Status (5)
Country | Link |
---|---|
US (5) | US9399619B2 (ja) |
EP (2) | EP2726459B1 (ja) |
JP (3) | JP5977347B2 (ja) |
CN (2) | CN106166157B (ja) |
WO (1) | WO2013006394A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019034943A (ja) * | 2012-12-27 | 2019-03-07 | ドレクセル ユニバーシティ | Hbv感染に対する新規抗ウイルス剤 |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106166157B (zh) | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物 |
TWI622578B (zh) | 2011-12-21 | 2018-05-01 | 諾維拉治療公司 | B型肝炎抗病毒劑 |
BR112015004192B1 (pt) * | 2012-08-28 | 2021-02-09 | Janssen Sciences Ireland Uc | sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b |
UA115069C2 (uk) | 2012-08-28 | 2017-09-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b |
WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
BR112015025052A2 (pt) * | 2013-04-03 | 2021-07-06 | Janssen Sciences Ireland Uc | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b |
JO3603B1 (ar) * | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
EA035500B1 (ru) * | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
EP3357906B1 (en) * | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
EA201690979A1 (ru) | 2013-11-14 | 2016-08-31 | Новира Терапьютикс, Инк. | Производные азепана и способы лечения инфекций гепатита в |
US9169212B2 (en) * | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
CN105980378B (zh) * | 2014-02-06 | 2019-09-27 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
CN106413402B (zh) | 2014-03-13 | 2020-10-30 | 美国印第安纳大学研究和技术公司 | 乙型肝炎核心蛋白变构调节剂 |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
CA2948580A1 (en) * | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
WO2015191907A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9765050B2 (en) * | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
CN107847762A (zh) * | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
WO2016168619A1 (en) | 2015-04-17 | 2016-10-20 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
TWI721016B (zh) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
KR101857714B1 (ko) * | 2016-02-05 | 2018-05-15 | 연세대학교 산학협력단 | 신규 아미드 화합물 및 이의 용도 |
WO2017155844A1 (en) | 2016-03-07 | 2017-09-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
SG11201807569WA (en) * | 2016-03-09 | 2018-10-30 | Univ Emory | Elimination of hepatitis b virus with antiviral agents |
SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
CN109843296A (zh) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
JOP20190024A1 (ar) * | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
WO2018053157A1 (en) | 2016-09-15 | 2018-03-22 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
KR102522060B1 (ko) | 2016-11-07 | 2023-04-14 | 아뷰터스 바이오파마 코포레이션 | 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법 |
WO2018086530A1 (zh) * | 2016-11-08 | 2018-05-17 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
JP2020506203A (ja) * | 2017-02-07 | 2020-02-27 | ヤンセン ファーマシューティカ エヌ.ベー. | 肝線維症の治療のための医薬品としてのスルファモイルアリール誘導体およびその使用 |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
US11078170B2 (en) | 2017-03-02 | 2021-08-03 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
KR102575605B1 (ko) | 2017-03-13 | 2023-09-05 | 어셈블리 바이오사이언시스, 인크. | B형 간염 코어 단백질 조정제의 제조 방법 |
US11098010B2 (en) | 2017-03-21 | 2021-08-24 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
EP3628674A4 (en) | 2017-05-04 | 2020-11-25 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | BICYCLIC NUCLEOCAPSID INHIBITORS AND THEIR USE AS MEDICINAL PRODUCTS IN THE TREATMENT OF HEPATITIS B. |
JP2020525490A (ja) | 2017-06-27 | 2020-08-27 | ヤンセン ファーマシューティカ エヌ.ベー. | ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染を治療する方法 |
CN109251212A (zh) | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
CN109251158B (zh) * | 2017-07-14 | 2023-05-23 | 上海长森药业有限公司 | 硫脒酰胺类化合物及其用于乙型肝炎治疗的用途 |
KR102556744B1 (ko) | 2017-08-28 | 2023-07-18 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
TW201912153A (zh) * | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | 用於治療b型肝炎的化合物、醫藥組合物及方法 |
EP3704119A1 (en) | 2017-11-02 | 2020-09-09 | AiCuris GmbH & Co. KG | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
MX2020004839A (es) | 2017-11-02 | 2020-10-16 | Aicuris Gmbh & Co Kg | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb). |
US11572372B2 (en) * | 2017-11-16 | 2023-02-07 | Medshine Discovery Inc. | Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds |
US20210079015A1 (en) * | 2017-11-17 | 2021-03-18 | Novartis Ag | Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b |
WO2019113175A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2019113173A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US11247965B2 (en) | 2017-12-11 | 2022-02-15 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
US20200407365A1 (en) | 2018-02-28 | 2020-12-31 | Novartis Ag | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2019206072A1 (zh) * | 2018-04-24 | 2019-10-31 | 浙江海正药业股份有限公司 | 磺酰胺芳基甲酰胺衍生物及其制备方法和用途 |
DE202019005471U1 (de) | 2018-06-11 | 2020-09-17 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B Kapsid-Assemblierungsmodulatoren |
EP3597653A1 (en) | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Cyclic inhibitors of hepatitis b virus |
EP3597637A1 (en) | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Inhibitors of hepatitis b virus |
CN108863860B (zh) * | 2018-07-27 | 2021-08-06 | 温州医科大学 | 一种n-取代苯基-3-磺酰氨基苯甲酰胺类化合物及其制备和抗乳腺癌活性的应用 |
CN108997176B (zh) * | 2018-07-27 | 2021-07-02 | 温州医科大学 | 一种4-氯-n-取代苯基-3-磺酰氨基苯甲酰胺类化合物及其制备和抗肿瘤应用 |
US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
EP3608326A1 (en) | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
JP2022508642A (ja) * | 2018-10-05 | 2022-01-19 | エモリー ユニバーシティ | モノマーおよびマルチマー抗hbv薬 |
US11560370B1 (en) | 2018-10-22 | 2023-01-24 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
EP3873488A4 (en) | 2018-10-31 | 2022-08-03 | The University of Sydney | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION |
UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
JP2022506351A (ja) | 2018-11-02 | 2022-01-17 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | B型肝炎ウイルス(hbv)に対して活性を有する新規ウレア6,7-ジヒドロ-4h-チアゾロ[5,4-c]ピリジン |
AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
UY38436A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
WO2020106816A1 (en) | 2018-11-21 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
CN111434665B (zh) * | 2019-01-11 | 2023-03-10 | 上海长森药业有限公司 | 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
CA3138385A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
JP2022530522A (ja) | 2019-04-30 | 2022-06-29 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | B型肝炎ウイルス(hbv)に対し活性な新規のインドール-2-カルボキサミド |
MX2021013086A (es) | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb). |
US20220227737A1 (en) | 2019-04-30 | 2022-07-21 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
EP3825318A1 (en) | 2019-11-25 | 2021-05-26 | Promidis S.r.l. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
EP3741762A1 (en) | 2019-05-23 | 2020-11-25 | Irbm S.P.A. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
UY38705A (es) | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
SG11202112590WA (en) | 2019-05-24 | 2021-12-30 | Assembly Biosciences Inc | Pharmaceutical compositions for the treatment of hbv |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247575A1 (en) * | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
CN111349056B (zh) * | 2020-04-16 | 2022-08-02 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
CN111393391B (zh) * | 2020-04-16 | 2022-07-26 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
WO2021216661A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
WO2021216656A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
EP4139000A1 (en) | 2020-04-22 | 2023-03-01 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
WO2023069544A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069547A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069545A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
CN115677545B (zh) * | 2022-10-28 | 2024-03-15 | 潍坊医学院 | 一种抗hbv磺胺苯甲酰胺类衍生物及其制备方法和应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US422547A (en) * | 1890-03-04 | Knife | ||
US3055905A (en) | 1958-03-04 | 1962-09-25 | Geigy Chem Corp | New sulphamyl benzamides |
GB912060A (en) | 1960-05-09 | 1962-12-05 | British Drug Houses Ltd | 4-chloro-3-sulphamylbenzanilides |
GB921520A (en) | 1960-10-10 | 1963-03-20 | British Drug Houses Ltd | 4-fluoro and 4-bromo-3-sulphamylbenzanilides |
US3602786A (en) * | 1970-06-22 | 1971-08-31 | Georgy Ignatievich Izhelya | Induction linear electric motor |
US4115155A (en) * | 1974-05-03 | 1978-09-19 | Bethlehem Steel Corporation | Low carbon high yield and tensile strength steel and method of manufacture |
GB9109557D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
JPH0959236A (ja) | 1995-08-23 | 1997-03-04 | Dai Ichi Seiyaku Co Ltd | ベンズアミド化合物 |
US5939423A (en) * | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
GB9800750D0 (en) | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
WO2006044645A2 (en) * | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
US20080021063A1 (en) * | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
US20100016310A1 (en) * | 2006-08-17 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
EP2581081A3 (en) * | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
WO2009018219A2 (en) * | 2007-07-28 | 2009-02-05 | University Of Chicago | Methods and compositions for modulating rad51 and homologous recombination |
CA2695071A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
US20100009970A1 (en) * | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JP5501226B2 (ja) * | 2008-04-24 | 2014-05-21 | Msd株式会社 | アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤 |
FR2933698A1 (fr) * | 2008-07-09 | 2010-01-15 | Servier Lab | Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
CN106166157B (zh) | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物 |
TWI622578B (zh) | 2011-12-21 | 2018-05-01 | 諾維拉治療公司 | B型肝炎抗病毒劑 |
US9657013B2 (en) | 2012-02-29 | 2017-05-23 | Baruch S. Blumberg Institute | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use |
-
2012
- 2012-06-29 CN CN201610312350.0A patent/CN106166157B/zh not_active Expired - Fee Related
- 2012-06-29 EP EP12807810.2A patent/EP2726459B1/en active Active
- 2012-06-29 EP EP16174324.0A patent/EP3085368A1/en not_active Withdrawn
- 2012-06-29 US US14/130,140 patent/US9399619B2/en active Active
- 2012-06-29 WO PCT/US2012/044775 patent/WO2013006394A1/en active Application Filing
- 2012-06-29 CN CN201280039363.5A patent/CN103889953B/zh not_active Expired - Fee Related
- 2012-06-29 JP JP2014519057A patent/JP5977347B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-18 US US14/975,239 patent/US9758477B2/en active Active
-
2016
- 2016-07-21 JP JP2016143481A patent/JP6516705B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-21 US US15/656,769 patent/US20170320818A1/en not_active Abandoned
-
2019
- 2019-04-16 JP JP2019077562A patent/JP2019151639A/ja active Pending
- 2019-07-02 US US16/459,665 patent/US20190337891A1/en not_active Abandoned
-
2020
- 2020-11-23 US US17/101,852 patent/US20210070703A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019034943A (ja) * | 2012-12-27 | 2019-03-07 | ドレクセル ユニバーシティ | Hbv感染に対する新規抗ウイルス剤 |
Also Published As
Publication number | Publication date |
---|---|
EP3085368A1 (en) | 2016-10-26 |
CN103889953B (zh) | 2016-06-08 |
CN106166157B (zh) | 2019-08-02 |
EP2726459B1 (en) | 2019-09-11 |
US9399619B2 (en) | 2016-07-26 |
US20140206666A1 (en) | 2014-07-24 |
JP2019151639A (ja) | 2019-09-12 |
WO2013006394A1 (en) | 2013-01-10 |
JP2017014225A (ja) | 2017-01-19 |
US20190337891A1 (en) | 2019-11-07 |
US9758477B2 (en) | 2017-09-12 |
JP6516705B2 (ja) | 2019-05-22 |
JP2014523901A (ja) | 2014-09-18 |
EP2726459A1 (en) | 2014-05-07 |
CN103889953A (zh) | 2014-06-25 |
US20160101074A1 (en) | 2016-04-14 |
EP2726459A4 (en) | 2014-12-31 |
CN106166157A (zh) | 2016-11-30 |
US20210070703A1 (en) | 2021-03-11 |
US20170320818A1 (en) | 2017-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5977347B2 (ja) | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 | |
JP6353460B2 (ja) | Hbv感染に対する抗ウイルス剤としての官能化ベンズアミド誘導体 | |
US9657013B2 (en) | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | |
JP6409001B2 (ja) | Hbv感染に対する新規抗ウイルス剤 | |
US20240100031A1 (en) | Pharmaceutical composition for preventing or treating viral infections containing piperlongumine-based compound as active ingredient | |
JP2016534049A (ja) | 内皮リパーゼ阻害を示す官能基化フラン−2−スルホンアミド | |
US20170305856A1 (en) | Novel diacylated and mono-acylated alkylated imino sugars exhibiting glucosidase inhibition and their method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150629 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150629 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20151126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160621 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160721 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5977347 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |